Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New sperm-sorting chip could boost IVF success rates

NCT ID NCT07369362

Disease control Sponsor: MotilityCount aps Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new microfluidic device, SwimCount Harvester, to standard sperm preparation methods in couples undergoing IVF with genetic testing (PGT-A). About 1,600 couples will be randomly assigned to one of the two methods. The goal is to see if the device leads to more usable embryos and a higher chance of having a normal embryo for transfer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Sperm sample available on day of egg retrieval * Female partner age 21-45 years undergoing IVF with PGT-A * Male partner age ≥ 21 years * Pre-processing volume ≥1mL * Pre-processing sperm concentration ≥1 million/mL * Pre-processing progressive motility ≥10% * Signed informed consent from both partners Exclusion Criteria: * • Surgical sperm retrieval required * Current standard of care with the SwimCount Harvester device

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aneuploidy rate are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aneuploidy infertility disorder male infertility

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aneuploidy rate Euploidy rate Infertility Invitro fertilization Male infertility

Contacts and locations

Locations

  • First Fertility

    Farmington, Connecticut, 06023, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.